SURVYR

AZN

AstraZeneca PLC
$170.08
−$1.98 (1.15%)Oct 27 close
Healthcare CompareTechnicals
1M3M6M1Y2Y
-8%+1%+10%+19%+28%Oct 2025Oct 2026Apr 202652w high $212.7152w low $153.41
AZNSPY
Wall St. Highest PT $240.00 (+41.1%) Wall St. Avg PT $206.66 (+21.5%)
$156$185$215$244$274POC $184Hi $240Avg $207
Underwater Drawdown %Max DD -25.4%Current -18.5%
0.0%-25.4%
Relative Strength vs SPY-11.3% vs SPYUnderperforming
+30%0%-30%
1W
+$1.26 (0.75%)
1M
+$3.50 (2.10%)
3M
−$2.40 (1.39%)
6M
−$16.60 (8.89%)
YTD
−$11.88 (6.53%)
1Y
+$3.69 (2.22%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
12 analysts · mean score 1.83
1 = Strong Buy · 5 = Sell
Strong Buy217%
Buy758%
Hold217%
Underperform18%
Sell00%
Wall Street consensus
Analyst price targets
Current price$170.08
Average target$206.66
+$36.58 (+21.5%) upsideaverage target vs current price
CurrentAverageMedian
Low$158.00
Median$208.00
High$240.00
12-month Wall Street target range
Recent analyst rating changes · 30
Initiated
2026-08-24 · CICC started covering AZN at Outperform
Upgrade
2025-02-13 · UBS upgraded AZN from Neutral to Buy
Upgrade
2024-11-20 · UBS upgraded AZN from Sell to Neutral
Upgrade
2024-09-11 · Erste Group upgraded AZN from Hold to Buy
Reiterated
2024-08-12 · TD Cowen reiterated Buy on AZN
Reiterated
2024-05-30 · Argus Research reiterated Buy on AZN
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$263.8B
P/E (last 12 months)25.4
P/E (next 12 months, estimated)15.0
52-week range$153.41 – $212.71
Revenue growth (latest quarter vs a year ago)+6.4%
Dividend yield1.86%
Analyst consensusBuy (12)
Average analyst price target$206.66 (+22%)

What they do

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin. It also provides Beyfortus, Kavigale, Evusheld, Fluenz/FluMist, Synagis, Kanuma, Ultomiris, Koselugo, Voydeya, Soliris, Strensiq.

Healthcare · Drug Manufacturers - General
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

No sector grades for AZN yet. Grades rank S&P 1500 stocks within their sector and refresh after each daily data run, so a stock outside that index or newly covered has none.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
Outside this model's universe or screens
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

AZN earningsNext report in 2 days
Next report · quarter Sep 2026
Fri Oct 30, 2026Before the open
EPS consensus$2.58
Revenue consensus$16.0B 15 analysts
Last 4 quarters · EPS vs estimate
Jul 27, 2026$1.32est $1.25+4.8%Above estimates
Apr 29, 2026$1.29est $1.27+1.4%Above estimates
Nov 6, 2025$1.19est $1.13+4.9%Above estimates
Jul 29, 2025$0.79est $0.88−10.7%Below estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · report time: Nasdaq earnings calendar · refreshed 2026-10-27 18:23:32 ET
24-0724-1125-0225-0425-0725-1126-0426-070.001.32
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-06-30$15.4B+6.4%
2026-03-31$15.3B–
2025-12-31$15.5B–
2025-09-30$15.2B–
2025-06-30$14.5B–

Recent dividends

2026-02-19: $2.153 · 2025-08-08: $1.030 · 2025-02-21: $2.100 · 2024-08-09: $1.000 · 2024-02-22: $1.970 · 2023-08-10: $0.930 · 2023-02-23: $1.970 · 2022-08-11: $0.930

News & catalysts

More news
AstraZeneca Highlights Breakthrough Cancer Data at ESMO 2026 Investor Update
Nasdaq · Oct 26
AstraZeneca's Tezspire Shows Sustained Benefits In Phase 3 Esophagitis Trial
Nasdaq · Oct 20
Should You Be Worried About Tempus AI Stock?
Trefis · Oct 20
Haleon And 2 British AI Healthcare Stocks To Watch
Simply Wall St. · Oct 18
European Indexes Largely Rise, Though AI Stocks Fall
The Wall Street Journal · Oct 13
Rating changes
Initiated
2026-08-24 · CICC started covering AZN at Outperform
Upgrade
2025-02-13 · UBS upgraded AZN from Neutral to Buy
Upgrade
2024-11-20 · UBS upgraded AZN from Sell to Neutral
Upgrade
2024-09-11 · Erste Group upgraded AZN from Hold to Buy
Reiterated
2024-08-12 · TD Cowen reiterated Buy on AZN
Reiterated
2024-05-30 · Argus Research reiterated Buy on AZN

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Sharma Mani
See Remarks · 2026-08-08
Buy
$3.2K
None
None · None
Sell
–
None
None · None
Sell
–

Stats refreshed 2026-10-27 18:23:32 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026